HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Collaborative Ocular Tuberculosis Study Consensus Guidelines on the Management of Tubercular Uveitis-Report 1: Guidelines for Initiating Antitubercular Therapy in Tubercular Choroiditis.

AbstractTOPIC:
An international, expert-led consensus initiative organized by the Collaborative Ocular Tuberculosis Study (COTS), along with the International Ocular Inflammation Society and the International Uveitis Study Group, systematically developed evidence- and experience-based recommendations for the treatment of tubercular choroiditis.
CLINICAL RELEVANCE:
The diagnosis and management of tubercular uveitis (TBU) pose a significant challenge. Current guidelines and literature are insufficient to guide physicians regarding the initiation of antitubercular therapy (ATT) in patients with TBU.
METHODS:
An international expert steering subcommittee of the COTS group identified clinical questions and conducted a systematic review of the published literature on the use of ATT for tubercular choroiditis. Using an interactive online questionnaire, guided by background knowledge from published literature, 81 global experts (including ophthalmologists, pulmonologists, and infectious disease physicians) generated preliminary consensus statements for initiating ATT in tubercular choroiditis, using Oxford levels of medical evidence. In total, 162 statements were identified regarding when to initiate ATT in patients with tubercular serpiginous-like choroiditis, tuberculoma, and tubercular focal or multifocal choroiditis. The COTS group members met in November 2018 to refine these statements by a 2-step modified Delphi process.
RESULTS:
Seventy consensus statements addressed the initiation of ATT in the 3 subtypes of tubercular choroiditis, and in addition, 10 consensus statements were developed regarding the use of adjunctive therapy in tubercular choroiditis. Experts agreed on initiating ATT in tubercular choroiditis in the presence of positive results for any 1 of the positive immunologic tests along with radiologic features suggestive of tuberculosis. For tubercular serpiginous-like choroiditis and tuberculoma, positive results from even 1 positive immunologic test were considered sufficient to recommend ATT, even if there were no radiologic features suggestive of tuberculosis.
DISCUSSION:
Consensus guidelines were developed to guide the initiation of ATT in patients with tubercular choroiditis, based on the published literature, expert opinion, and practical experience, to bridge the gap between clinical need and available medical evidence.
AuthorsRupesh Agrawal, Ilaria Testi, Sarakshi Mahajan, Yew Sen Yuen, Aniruddha Agarwal, Onn Min Kon, Talin Barisani-Asenbauer, John H Kempen, Amod Gupta, Douglas A Jabs, Justine R Smith, Quan Dong Nguyen, Carlos Pavesio, Vishali Gupta, Collaborative Ocular Tuberculosis Study Consensus Group
JournalOphthalmology (Ophthalmology) Vol. 128 Issue 2 Pg. 266-276 (02 2021) ISSN: 1549-4713 [Electronic] United States
PMID32115264 (Publication Type: Consensus Development Conference, Journal Article, Practice Guideline, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2020 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
Chemical References
  • Antitubercular Agents
  • Glucocorticoids
Topics
  • Antitubercular Agents (therapeutic use)
  • Chemotherapy, Adjuvant
  • Delphi Technique
  • Drug Therapy, Combination
  • Eye Infections, Bacterial (diagnosis, drug therapy, microbiology)
  • Glucocorticoids (therapeutic use)
  • Humans
  • Multifocal Choroiditis (diagnosis, drug therapy, microbiology)
  • Radiography, Thoracic
  • Retrospective Studies
  • Surveys and Questionnaires
  • Tomography, X-Ray Computed
  • Tuberculin Test
  • Tuberculosis, Ocular (diagnosis, drug therapy, microbiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: